Neuroblastoma: The basis for cure in limited-resource settings.
low- and middle-income countries
management
neuroblastoma
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
22
12
2020
received:
09
11
2020
accepted:
08
01
2021
pubmed:
4
2
2021
medline:
3
2
2022
entrez:
3
2
2021
Statut:
ppublish
Résumé
Neuroblastoma (NB) contributes the most to the mortality of childhood malignancies worldwide. The disease spectrum is heterogenous and the management complex and costly, especially in advanced disease or disease with adverse biology. In low- and middle-income countries (LMICs) the majority of NB presents in advanced stages. Therefore, with limited resources and poor prognosis the treatment of NB is often not a priority. The aim of the study was to evaluate the research activities and perceptions of the management of NB that determine the research and treatment approaches in LMICs. Data were sourced from https://www.clinicaltrials.gov/ identifying NB trials open to LMIC. Abstracts on NB research presented at the International Society for Paediatric Oncology (SIOP) Congresses between 2014 and 2020 were evaluated according to income status. An online survey evaluating medical views on NB in LMICs and the effect on the management was conducted. Descriptive analysis was done. Where appropriate categorical association between covariates was assessed using the Pearson chi-square (χ There were 15/562 (2.7%) trials open to LMIC. Only six of 138 (4.3%) LMIC participated in NB trials. Of the 688 abstracts presented between 2014 and 2020 at the SIOP International Congress on NB as primary subject, 297 (42.7%) were from LMICs. Only two were from low-income countries (LICs). Sixty-one countries responded to the NB survey. Positive views towards NB management were present when treatment was based on a national protocol, the availability of trimodal or advanced treatment options were present, and when a balance of metastatic or local disease were treated. Management of NB in LMICs should include increased advocacy and research as well as implementation of national management strategies.
Sections du résumé
BACKGROUND
Neuroblastoma (NB) contributes the most to the mortality of childhood malignancies worldwide. The disease spectrum is heterogenous and the management complex and costly, especially in advanced disease or disease with adverse biology. In low- and middle-income countries (LMICs) the majority of NB presents in advanced stages. Therefore, with limited resources and poor prognosis the treatment of NB is often not a priority. The aim of the study was to evaluate the research activities and perceptions of the management of NB that determine the research and treatment approaches in LMICs.
METHODS
Data were sourced from https://www.clinicaltrials.gov/ identifying NB trials open to LMIC. Abstracts on NB research presented at the International Society for Paediatric Oncology (SIOP) Congresses between 2014 and 2020 were evaluated according to income status. An online survey evaluating medical views on NB in LMICs and the effect on the management was conducted. Descriptive analysis was done. Where appropriate categorical association between covariates was assessed using the Pearson chi-square (χ
RESULTS
There were 15/562 (2.7%) trials open to LMIC. Only six of 138 (4.3%) LMIC participated in NB trials. Of the 688 abstracts presented between 2014 and 2020 at the SIOP International Congress on NB as primary subject, 297 (42.7%) were from LMICs. Only two were from low-income countries (LICs). Sixty-one countries responded to the NB survey. Positive views towards NB management were present when treatment was based on a national protocol, the availability of trimodal or advanced treatment options were present, and when a balance of metastatic or local disease were treated.
CONCLUSION
Management of NB in LMICs should include increased advocacy and research as well as implementation of national management strategies.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28923Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Kruk M, Nigendo G, Knaul FM. Redesigning primary care to tackle the global epidemic of noncommunicable disease. Am J Public Health. 2015;105(3):431-437.
Lall D, Engel N, Devadasan N, et al. Models of care for chronic conditions in low/middle-income countries: a ‘best fit’ framework synthesis. BMJ Glob Health. 2018;3:01077.
International Society of Paediatric Oncology. WHO Global Initiative for Childhood Cancer. https://siop-online.org/who-global-initiative-for-childhood-cancer/. Accessed October 4, 2020.
World Health Organization. Improving Cancer Cure rates. https://www.who.int/activities/improving-childhood-cancer-cure-rate. Accessed October 4, 2020.
Bhatnagar SN, Sarin YK. Neuroblastoma: a review of management and outcome. Indian J Pediatr. 2012;79(6):787-792.
Heck J, Ritz B, Hung RJ, Hashbe M, Boffetta P. The epidemiology of neuroblastoma: a review. Paediatr Perinat Epidemiol. 2009;23:125-143.
Brodeur G. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203-216.
Moussa E, Fawzy M, Younis A, et al. Combined treatment strategy and outcome of high-risk neuroblastoma: experience of the Children's Cancer Hospital-Egypt. J Cancer Ther. 2013;4(9):1435-1442.
Moreno F, Lopez Marti J, Palladino M, Lobos P, Gualtieri A, Cacciavillano W. Childhood neuroblastoma: incidence and survival in Argentina. Report from the National Pediatric Cancer Registry, ROHA Network 2000-2012. Pediatr Blood Cancer. 2016;63(8):1362-1367.
Van Heerden J, Hendricks M, Geel J, et al. Overall survival for neuroblastoma in South Africa between 2000 and 2014. Pediatr Blood Cancer. 2019;66:e27944.
Qualtrics XM Software. Version 2.0. Copyright 2020. Provo, UT: Qualtrics; 2020. https://www.qualtrics.com/.
Schrepp M. On the usage of Cronbach's alpha to measure reliability of UX scales. J Usability Stud. 2020;15(4):247-258.
World Health Organization. Meeting on Child Health Redesign in the WHO European Region. 31 October-2 November 2017, Copenhagen, Denmark. http://www.euro.who.int/child-health-redesign-meeting-eng. Accessed October 4, 2020.
EURORDIS. What is a Rare Disease? http://www.eurordis.org/about-rare-diseases. Accessed September 28, 2020.
orpha.netabout rare diseases. About Rare Diseases. http://www.orpha.net/consor/cgibin/Education_AboutRareDiseases. Accessed September 28, 2020.
Rodriguez-Galindo C, Friedrich P, Alcasabas P, et al. Toward the cure of all children with cancer through collaborative efforts: pediatric oncology as a global challenge. J Clin Oncol. 2015;33(27):3065-3073.
Scherer RW, Saldanha IJ. How should systematic reviewers handle conference abstracts? A view from the trenches. Syst Rev. 2019;8(11):264.
Parikh N, Howard S, Chantada G, et al. SIOP-PODC adapted risk stratification and treatment guidelines: recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer. 2015;62(8):1305-1316.
van Heerden J, Kruger M. Management of neuroblastoma in limited-resource settings. World J Clin Oncol. 2020;11(8):629-643.
National Cancer Institute. Wilms Tumor and Other Childhood Kidney Tumors Treatment. Prognosis and Prognostic Factors for Wilms Tumor. NCI. https://www.cancer.gov/types/kidney/hp/wilms-treatment-pdp. Accessed October 2020.
National Cancer Institute. Treatment Option Overview for Retinoblastoma. www.cancer.gov/types/retinoblastoma/hp/retinoblastoma-treatment-pdq. Accessed October 2020.
Salman Z, Kababri M, Hessissen L, et al. An intensive induction protocol for high-risk neuroblastoma in Morocco. J Glob Oncol. 2016;2(3_suppl):80s-81s.
Avanzini S, Pio L, Erminio G, et al. Image-defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy-induced variation, and impact on surgical outcomes. Pediatr Blood Cancer. 2017;64:e26605.
Pohl A, Erichsen M, Stehr M, Hubertus J, Bergmann F, Kammer B. Image-defined risk factors correlate with surgical radicality and local recurrence in patients with neuroblastoma. Klin Pädiatr. 2016;228(03):118-123.
Parhar D, Joharifard S, Lo AC, Schlosser MP, Doadu OO. How well do image-defined risk factors (IDRFs) predict surgical outcomes and survival in patients with neuroblastoma? A systematic review and meta-analysis. Pediatr Surg Int. 2020;36:897-907.
Matthyssens LE, Nuchtern JG, Van De Ven CP, et al. A novel standard for systematic reporting of neuroblastoma surgery: the International Neuroblastoma Surgical Report Form (INSRF): a joint initiative by the pediatric oncological cooperative groups SIOPEN, COG, and GPOH. Ann Surg. 2020. https://doi.org/10.1097/sla.0000000000003947
Lau SCD, Unni MNM, Teh KH, et al. Autologous stem cell transplantation following high-dose chemotherapy in children with high-risk neuroblastoma: practicality in resource-limited countries. Pediatr Blood Cancer. 2020;67:e28176.
Jain R, Hans R, Totadri S, et al. Autologous stem cell transplant for high-risk neuroblastoma: achieving cure with low-cost adaptations. Pediatr Blood Cancer. 2020;67:e28273.
Harif M, Barsaoui S, Benchekroun S, et al. Treatment of B-cell lymphoma with LMB modified protocols in Africa: report of the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer. 2008;50(6):1138-1142.
Sirohi B. Cancer care delivery in India at the grassroot level: improve outcomes. Indian J Med Paediatr Oncol. 2014;35(3):187-191.
Selby P, Liu L, Downing A, et al. How can clinical research improve European health outcomes in cancer? J Cancer Policy. 2019;20:100182.
Brown BB, Patel C, McInnes E, et al. The effectiveness of clinical networks in improving quality of care and patient outcomes: a systematic review of quantitative and qualitative studies. BMC Health Serv Res. 2016;16:360.
Syrimi E, Lewison G, Sullivan R, Kearns P. Analysis of global pediatric cancer research and publications. J Glob Oncol. 2020;6:9-18.
Rodriguez-Galindo C, Friedrich P, Alcasabas P, et al. Toward the cure of all children with cancer through collaborative efforts: pediatric oncology as a global challenge. J Clin Oncol. 2015;33(27):3065-3073.
Xu K, Soucat A, Kutzin J, et al. Public Spending on Health: A Closer Look at Global Trends. Geneva: World Health Organization; 2018. https://apps.who.int/iris/bitstream/handle/10665/276728/WHO-HIS-HGF-HF-WorkingPaper-18.3-eng.pdf?ua=1